244 related articles for article (PubMed ID: 25238025)
1. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Sykes AP; Kemp GL; Dobbins R; O'Connor-Semmes R; Almond SR; Wilkison WO; Walker S; Kler L
Diabetes Obes Metab; 2015 Jan; 17(1):98-101. PubMed ID: 25238025
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.
Sykes AP; O'Connor-Semmes R; Dobbins R; Dorey DJ; Lorimer JD; Walker S; Wilkison WO; Kler L
Diabetes Obes Metab; 2015 Jan; 17(1):94-7. PubMed ID: 25223369
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [
